MedTrace Logo

Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)

NCT00780351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2009-10-23

No results posted yet for this study

Summary

1. Sustained low efficiency daily hemodiafiltration(SLEDD-f) is a kind of renal replacement therapy with high-flux dialyser membrane (helixone).
2. The pore size of helixone is larger than most antibiotics, and vancomycin is supposed to be removed during dialysis.
3. Our study wants to find the amount of vancomycin removed during SLEDD-f, and try to find the most appropriate dose regimen for this kind of patients.

Conditions

  • Acute Renal Failure

Interventions

DEVICE

sustained low efficiency daily hemodiafiltration (SLEDD-f)

vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Fe-Lin L Wu, MSCP, Ph.D. · School of pharmacy, Graduate institute of clinical pharmacy, Department of Pharmacy of National Taiwan University Hospital, College of Medicine, National Taiwan University

  • Wen-Je Ko, MD, PhD · Department of Surgery, National Taiwan University Hospital, College of Medicine, National Taiwan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Completion
2009-08-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780351 on ClinicalTrials.gov